LRFN2 and Parkinson disease: Similarly, levels of SALM1/LRFN2 proteins were found to be substantially decreased in postmortem brains of patients with neurodegenerative disorders associated with cognitive declines such as Alzheimer’s disease and Parkinson’s disease with dementia (Bereczki et al., 2018).